Monday, March 8 - Wednesday, March 10
Exhibition Hall - Booth # 1913
Wednesday, March 10
Join Roche for four separate poster presentations describing their work with CDI iCell™ Cardiomyocytes for cardiotoxicology research incorporating a range of techniques including microelectrode arrays,
manual patch clamp, profiling compounds with cardiotoxic potential, and high content imaging.
Monday, March 8
9:15am -noon
Room 250
Human Inducible Pluripotent Stem Cell Derived in vitro Models - The Path to a Better Understanding of Individual Biology and Their Utility in Drug Discovery & Development
- Chris Kendrick-Parker, CDI
Application of Stem Cell-derived Cardiomyocytes in Toxicology and Safety Pharmacology
- Kyle Kolaja, Hoffman-LaRoche
Pharmaceutical Perspectives on Introduction of Regenerative Medicine Concepts into the Existing Pharmaceutical Paradigm
- Ruth McKernan, Pfizer
Developing Stem Cell-based Therapies: FDA Product and Preclinical Regulatory Considerations
- Mercees Serabian, US FDA
How the Understanding of the Biology of Inducible Pluripotent Stem Cells Will Evolve: Predictions on Methods of Stem Cell Induction and the Impact on Cell-based Therapy
- James Thomson, CDI; Morgridge Institute for Research, and UW-Madison
Chairpersons: Hoffman LaRoche & CDI